SGT-610 (patidegib gel, 2%) — Topline data
Nov 2026
Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026Source filing
SLGL biotech catalysts & pipeline
SOL-GEL TECHNOLOGIES LTD · Data as of 2026-09-08
Upcoming catalysts
topical patidegib — Topline data
Nov 2026
With last patient last visit expected in September 2026 and top-line results anticipated in late November 2026, we are approaching the culmination of several years of work aimed at establishing topical patidegib as the first treatment designed to prevent the development of new basal cell carcinomas in patients with Gorlin syndrome.Source filing